In a proof-of-concept study published in PNAS Nexus on 20 March 2026, Fang Song and colleagues showed that high-pressure freezing (HPF) can cryopreserve 2D cell monolayers and 3D spheroids using 20–30% v/v penetrable cryoprotective agent (CPA), while suppressing ice crystallization and reducing fracture damage. The team applied pressure around 2,000 times atmospheric pressure and froze samples in milliseconds; HPF-treated monolayers showed higher post-thaw viability and better substrate retention than plunge freezing, and spheroids retained better cell-cell adhesion and metabolic activity.
The technical significance is direct: pressure can substitute for some chemical CPA load, which matters because CPAs are often toxic at the concentrations needed to prevent ice. The study also found that dextran, a nonpenetrating CPA, prevented fracture formation during vitrification, and HPF samples were described as transparent and fracture-free even without penetrable CPAs, indicating a pathway toward less chemically harsh preservation systems for cells and potentially more complex tissues.
For the Ark, this strengthens the case for dual-track biopreservation R&D: high-pressure vitrification hardware, reduced-CPA formulations, and downstream warming methods should be evaluated together as a systems stack. Priority monitoring targets are scalability beyond monolayers and spheroids, compatibility with bulk tissues and reproductive cells, pressure-vessel reliability, and whether HPF can be integrated with future nanowarming or rapid-uniform-thaw technologies for long-term biological vaults.